Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
SUPN > SEC Filings for SUPN > Form 8-K on 26-Apr-2013All Recent SEC Filings

Show all filings for SUPERNUS PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro

Form 8-K for SUPERNUS PHARMACEUTICALS INC


26-Apr-2013

Regulation FD Disclosure, Other Events, Financial Statements and Exh


Item 7.01 Regulation FD Disclosure

Supernus Pharmaceuticals, Inc. (the "Company") is disclosing under Item 7.01 of this Current Report on Form 8-K the information attached to this report as Exhibit 99.1. This information, which has not been previously reported, represents the April 2013 Presentation by Management to the lenders under the Company's Convertible Senior Secured Notes and to other prospective lenders.

The Company expects to use approximately $21.0 million of the net proceeds of the offering described in Item 8.01 below to repay in full its borrowings under and terminate its secured credit facility and the remainder of the net proceeds to fund the commercialization of its approved and tentatively approved drugs, Oxtellar XR and Trokendi XR ($24.0 million), to continue development of its pipeline products and for other general corporate purposes ($19.0 million). This financing has been designed to take the Company through cash flow break even.

The Company is furnishing the information in this Current Report on Form 8-K to comply with Regulation FD. Such information shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.



Item 8.01 Other Events

On April 26, 2013, Supernus issued a press release announcing the pricing of its offering of $75.0 million aggregate principal amount of 7.50% Convertible Senior Secured Notes due 2019 (the "Convertible Notes") in a private offering pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Supernus also granted to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $15.0 million aggregate principal amount of the Convertible Notes. The sale of the Convertible Notes is expected to close on May 3, 2013, subject to customary closing conditions.



Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following documents are furnished as Exhibits pursuant to Item 7.01 and 8.01 hereof:

Exhibit 99.1 - April 2013 Management Presentation.

Exhibit 99.2 - Press Release dated March 26, 2013 of the Company announcing the pricing of the offered $75.0 million aggregate principal amount of 7.50% Convertible Senior Secured Notes.


  Add SUPN to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for SUPN - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.